Genzyme's Fabrazyme at home and abroad

In my previous post, Fabry Disease Patients Have New Option, I mentioned that Shire's product, Replagal, was widely available outside the US, in competition abroad with Genzyme's product, Fabrazyme, which is the only drug approved in the US. In pursuing their various options to obtain full doses of Fabrazyme for their life-threatening disease, American patients have sued Genzyme and asked for legislation to prevent Genzyme from exporting Fabrazyme to countries where Replagal is available, while imposing rationing at home. Ed Silverman has two especially pertinent posts at his Pharmalot blog.

Genzyme Charged with Double Standard by Patients
Genzyme Charged with Double Standard, Again